Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

H2 2022 sees 10 billion drop in total forecast sales of COVID-19 vaccines between 2021 and 2028, says GlobalData

Despite the continued success of prophylactic vaccines such as Pfizer/BioNTech’s messenger RNA (mRNA) vaccine Comirnaty and spikes in COVID-19 case numbers over the winter, prophylactic COVID-19 vaccine sales forecasts have seen an average decline between H1 2022 and H2 2022 of 7% in their predicted total forecast sales between 2022 and 2028, says GlobalData, a […]
Read more

GlobalData slashes Moderna COVID-19 vaccine Spikevax sales forecast amid strong competition

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5 billion in 2022. However, increasing competition from Pfizer’s Comirnaty, Novavax’s Nuvaxovid, and COVID-19 therapeutics has forced GlobalData to slash Spikevax’s average annual sales forecast by 23% between H1 and H2 2022 in its Coronavirus Disease 2019 (COVID-19) Sector Forecast reports. Kevin […]
Read more

Uptake of long-awaited Humira biosimilar in US to be dictated by price, says GlobalData

Following the launch of Amgen’s Amjevita (adalimumab-atto), the first biosimilar to AbbVie’s cash-cow immunology biologic therapy, Humira (adalimumab), in the US on 31 January; Vinie Varkey, Managing Analyst, Immunology at GlobalData, a leading data and analytics company, offers her view: “For AbbVie, while the threat of adalimumab biosimilars to its blockbuster therapy are finally tangible […]
Read more

With expanded approval for Brukinsa, BeiGene poised to lead chronic lymphocytic leukemia market, says GlobalData

The FDA has recently granted expanded approval for BeiGene’s oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) or small Lymphocytic Leukemia (SLL). Brukinsa has gained approval after outperforming Abbvie’s Imbruvica, which has been the standard of care in CLL for almost a decade. Brukinsa should largely replace Imbruvica […]
Read more

Takeda newly approved NSCLC therapy Exkivity still has room for better treatment outcome in China, observes GlobalData

Takeda‘s Exkivity (mobocertinib) is the first and only targeted therapy to be approved for locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 20 insertions (exon20ins)-positive non-small cell lung cancer (NSCLC) in China. The drug is approved under the National Medical Products Administration’s Breakthrough Therapy program for second-line treatment. However, there still exists room […]
Read more

Pharma companies that develop vaccines with efficacy against Omicron variants will gain competitive advantage in China, says GlobalData

Omicron lineages BA.5.2 and BF.7 account for 97.5% of all local infections in China, according to the Chinese Center for Disease Control and Prevention. With new cases spreading rapidly, the National Health Commission (NHC) announced a national fourth booster vaccination campaign. Consequently, Chinese vaccine developers are focused on expanding their COVID-19 pipelines to include targeted […]
Read more

Intercept Pharmaceuticals’ obeticholic acid could be first drug to be approved for NASH, says GlobalData

Intercept Pharmaceuticals’ obeticholic acid could be first drug to be approved for NASH, says GlobalData Following FDA’s acceptance for Intercept Pharmaceuticals’ resubmission of its new drug application (NDA) for obeticholic acid (OCA) in patients with pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis (NASH) in December 2022 Sravani Meka, Senior Immunology Analyst at GlobalData, a leading […]
Read more

Obesity therapy by Versanis Bio sees advantageous MoA and reduced treatment days but challenged by pricing and hospital administration, says GlobalData

Following Versanis Bio’s recent announcement that enrolment had begun for Phase IIb trial BELIEVE on bimagrumab (BYM338); Sara Reci, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Bimagrumab has the potential to address key unmet needs in the obesity space. One advantage is its novel mechanism of action (MoA). Currently, […]
Read more

Genetic map of cells linked to endometriosis could help to improve treatment options, says GlobalData

Following the news that scientists at Cedars-Sinai have successfully mapped the cellular changes linked to endometriosis; Amy Murray, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “Despite its high prevalence and cost, endometriosis remains an understudied disease. This lack of research has greatly limited understanding and slowed much-needed innovation in treatment […]
Read more

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says GlobalData

Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease (AD) in patients with early AD. Achieving full approval will be crucial for Leqembi’s prospects as the US Centers for Medicare and Medicaid […]
Read more

Healthcare industry professionals’ optimism regarding pharma industry’s growth prospects is fading, finds GlobalData

The pharmaceutical industry is considered to be one of the most stable sectors even when pandemics, economic or geopolitical crises hit markets. However, even the pharmaceutical industry is not immune to the uncertainty in business conditions that 2023 may bring, finds GlobalData, a leading data and analytics company. A survey* taken from GlobalData’s report, ‘The State of the Biopharmaceutical Industry […]
Read more

​​​​​​​T2D market will reach $136.2 billion in 2029 driven by the launch of novel GLP-1s and once-weekly basal insulin therapies, says GlobalData

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple ‘me-too’, generic and biosimilar drugs entering the market. Growth will be primarily driven by the launch of novel blockbuster therapies and an increasing diagnosed prevalent population across the nine major markets (9MM)*, notes GlobalData, a leading data and analytics company. According to GlobalData’s latest […]
Read more

Western companies to play key role in improving cardiovascular disease management approach in China, says GlobalData

Cardiovascular diseases (CVDs) continue to be the leading cause of death globally, with China being no exception. As domestic companies are mostly involved in providing generic drugs for CVDs, China is heavily reliant on foreign players. Against this backdrop, key foreign players will play a crucial role in improving the overall cardiovascular disease management approach […]
Read more
1 … 38 39 40 41 42 … 108